Most patients with stage four cancer are not considered candidates for definitive radiotherapy because existing technology can’t efficiently track and treat multiple tumors. As well, treatment plans are not based on the real-time location of the tumor, but rather on anatomic surrogates or other implanted fiducials. To combat these limitations, complexity is added to both treatment planning and patient setup and margins of healthy tissue are added to the gross tumor volume (GTV) to a degree that conventional radiotherapy is not feasible for metastatic disease.
Simply put, there is no better fiducial than the tumors themselves from which to plan and deliver treatment. With BgRT, we eliminate the burden of fiducials or gating. And using tracked delivery, we avoid irradiating an entire ITV. With these advances, RefleXion Therapy aims to enable efficient treatment of multiple tumors in parallel during a single session. The machine bases radiotherapy delivery on precise, real-time tumor locations, so the treatment plan can include multiple tumors during the same fraction, a potential game-changing advance for metastatic disease. RefleXion’s patented BgRT delivers high doses of radiation for a powerful impact to the tumor, while sparing the surrounding healthy tissue to enable radiotherapy for people with advanced cancers for the first time.